RYTM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
92.1M
+29.3%
71.3M
+18.5%
60.1M
+5.0%
57.3M
+11.6%
51.3M
Cost of Revenue
12.2M
+36.2%
8.9M
+24.8%
7.2M
+49.0%
4.8M
-12.7%
5.5M
Gross Profit
80.0M
+28.3%
62.3M
+17.7%
53.0M
+1.0%
52.5M
+14.5%
45.8M
Operating Expenses
119.2M
+7.5%
110.9M
+5.3%
105.3M
+5.8%
99.5M
+1.1%
98.5M
R&D
52.5M
+20.8%
43.4M
+4.1%
41.7M
-0.7%
42.0M
-8.7%
46.0M
SG&A
66.8M
-1.0%
67.4M
+6.1%
63.6M
+10.6%
57.5M
+9.6%
52.4M
Operating Income
-39270000
+19.1%
-48552000
+7.3%
-52361000
-11.3%
-47063000
+10.6%
-52653000
EBITDA
-39022000
+19.2%
-48301000
+7.3%
-52109000
-11.4%
-46791000
+10.6%
-52349000
Net Income
-41369000
+16.1%
-49298000
+11.4%
-55639000
-17.1%
-47505000
+10.2%
-52904000
EPS (Basic)
$-0.61
+16.4%
$-0.73
+12.0%
$-0.83
-13.7%
$-0.73
+11.0%
$-0.82
EPS (Diluted)
$-0.61
+16.4%
$-0.73
+12.0%
$-0.83
-13.7%
$-0.73
+11.0%
$-0.82
Shares (Diluted)
69.0M
+0.7%
68.6M
+0.9%
68.0M
+1.6%
66.9M
+1.0%
66.3M
Rhythm Pharmaceuticals (RYTM) — Financials